Author

Shoshy Alam Brinch

Oslo University Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:protein folding & dynamics· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Jo WaaleriD· 3 shared Albert Galera‐PratiD· 2 shared Chiara BosettiiD· 2 shared Lari LehtiöiD· 2 shared María Candamo-LouridoiD· 2 shared Maureen Tania Meling· 2 shared Alexandra Gade· 1 shared Anita WegertiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

Jo WaalerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Discovery of Tankyrase scaffolding inhibitor specifically targeting the ARC4 peptide binding domain

Chiara Bosetti, Albert Galera‐Prat, Sven T. Sowa, Alexandra Gade, Cláudia Braga, Shoshy Alam Brinch, Faranak Nami, Johan Pääkkönen, Veeti Pulju, Maureen Tania Meling, María Candamo-Lourido, Jo Waaler, Mads H. Clausen, L. Lehtiö

The paper identifies a Tankyrase scaffolding inhibitor, S8 (ARCher-142), that selectively targets the ARC4 peptide binding domain with 8 µM potency.

Structure · Jan 30, 2026Peer-reviewedBiochemistry

Tankyrase inhibition demonstrates anti-fibrotic effects in preclinical pulmonary fibrosis models

Shoshy Alam Brinch, Ida Johnsen, Lena Willmer, Ole Vidhammer Bjørnstad, Teresa Lucifora, Karl Martin Forbord, María Candamo-Lourido, Maureen Tania Meling, Ingrid Lofthus Morken, Martin Frank Strand, Danny David Jonigk, Patrick Zardo, Hans‐Gerd Fieguth, Christina Hesse, Mark Alexander Skarsfeldt, , Jo Waaler

This study shows that the TNKS inhibitor OM-153 reduces fibrosis markers and ECM expression in multiple preclinical IPF models by inhibiting WNT/β-catenin and YAP signaling.

bioRxiv · Nov 13, 2025 · PreprintCell Biology

Substitutions at the C-8 position of quinazolin-4-ones improve the potency of nicotinamide site binding tankyrase inhibitors

Chiara Bosetti, Dionysis Kampasis, Shoshy Alam Brinch, Albert Galera‐Prat, Maria Karelou, Saurabh Singh Dhakar, Juho Alaviuhkola, Jo Waaler, Lari Lehtiö, Ioannis K. Kostakis

This study identifies C-8 position substitutions in quinazolin-4-ones that enhance the potency and selectivity of tankyrase inhibitors by improving interactions with TNKS2.

European Journal of Medicinal Chemistry · Feb 15, 2025Peer-reviewedBiochemistry